Description du projet
Association entre l’infection par le VRS et l’asthme
Le virus respiratoire syncytial (VRS) est un agent pathogène respiratoire courant et une cause majeure de bronchiolite et de pneumonie, en particulier chez les jeunes enfants et les adultes plus âgés. Le VRS est lié au développement de l’asthme et d’autres affections respiratoires chroniques. Le projet CLARITY, financé par l’UE, vise à identifier les facteurs de risque génétiques et les mécanismes liés à la bronchiolite sévère induite par le VRS chez les nourrissons. À partir de cohortes estoniennes et espagnoles, les chercheurs utiliseront l’IA pour analyser les données et identifier les altérations et les perturbations des processus cellulaires, moléculaires et physiologiques causés par le VRS. Les résultats du projet permettront d’identifier des composés médicamenteux potentiels contre l’asthme déclenché par le VRS.
Objectif
Chronic respiratory diseases are non-communicable diseases for which infections by several respiratory viruses and human genetics constitute major risk factors. The molecular and physiological mechanisms of how these viral infections cause and contribute to non-communicable disease development are unknown.
Respiratory syncytial virus (RSV) is a virus that infects nearly all infants before the age of 2 years and that is linked to asthma development. We propose an integrative approach to identify genetic risk factors and mechanisms underlying virus-induced asthma. Specifically, using two national cohorts (Estonian and Spanish), we will identify human genetic risk factors and RSV strains that contribute to severe bronchiolitis. We analyse how RSV perturbs intracellular networks to change cellular properties that trigger asthma development. We will use Artificial Intelligence (AI)-based techniques to integrate generated data with the current biological knowledge, to generate RSV-induced perturbation signatures and to identify drug-like compounds able to revert the effects of the RSV-induced perturbations. We will validate both mechanisms and candidate compounds in patient derived airway organoid models and, when promising, in a controlled human infection model trial.
CLARITY will impact the understanding, prevention and possibly treatment of virus-triggered asthma. The results will enable development of a genetic risk score for long-term asthma development that enables personalised prevention campaigns, which will be developed jointly with patient groups. The molecular mechanisms discovered, and the drug-like compounds that revert the perturbation signatures, will enable development of mechanism-targeted drugs. Fundamentally, the mechanisms identified in this specific model for a strong viral contribution to non-communicable disease will likely represent general mechanisms of how viral infections cause onset and development of other non-communicable diseases.
Champ scientifique
- natural sciencescomputer and information sciencesartificial intelligence
- medical and health sciencesclinical medicinepneumologyasthma
- natural sciencesbiological sciencesmicrobiologyvirology
- medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses
- medical and health sciencesbasic medicinemedical genetics
Mots‑clés
Programme(s)
Thème(s)
Régime de financement
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinateur
3584 CX Utrecht
Pays-Bas